Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 7711 results

  1. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Transcatheter tricuspid valve replacement for the reduction of tricuspid regurgitation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  4. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  6. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development

  8. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  9. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  11. Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448

    Awaiting development [GID-TA11564] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    In development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486

    Awaiting development [GID-TA11623] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development